"Our life science practice possesses unique experience and capability in national and international healthcare regulation."
In Conversation
"We have a solid strategy for emerging markets, and – despite our smaller size – we actually follow the same approach as some multinational companies."
"One of the challenges I am facing when trying to implement the build out of our Canadian affiliate is to determine a balance between leveraging shared…
"In fact, Poland has some of the lowest access of innovative drugs in the EU within the oncology field, considerably less than Germany and the UK."
"Although the UK is a fantastic place to do business, the NHS’ slow uptake of new products can be frustrating for the pharmaceutical industry."
"As we intend to grow within the next five years, our first challenge to overcome will be our cash flow, which means that we need to…
"The government has been slow to adapt to the pace of the changing landscape of diabetes treatment and we need this to change for the sake…
On the positive side, UK-based biotech companies are raising considerable venture capital and two or three international companies have recently announced they are making new investments…
"It's important to recognize that generic competition does not only reduce cost and increase patient access to medicines, it spurs innovation."
"There are jurisdictions where the government has acknowledged its role in enabling innovation adoption and they have done a great job of coordinating the actions of…
"We are committed to reducing national barriers and complexities to launching products and to making our regulatory processes as user friendly as possible without cutting corners…
Quebec provides us with low cost, green power, and an economical water source. On top of that, being located centrally in Canada is useful logistically
